GUIDELINES FOR THE MANAGEMENT OF DELIRIUM IN ADVANCED CANCER
|
|
- Janice Walker
- 5 years ago
- Views:
Transcription
1 GUIDELINES FOR THE MANAGEMENT OF DELIRIUM IN ADVANCED CANCER 14.1 GENERAL PRINCIPLES Delirium can be defined as: A transient organic brain syndrome characterised by the acute onset of disordered arousal and cognition, accompanied by disturbances of perception and psycho-motor behaviour. 1 The prevalence of delirium in advanced cancer is between 25-80%. It often has multiple aetiologies. 2, 3 Delirium is often unrecognised in patients with advanced cancer but early detection may lead to improved patient outcomes. 3, GUIDELINES Assessment of Delirium Delirium is a clinical diagnosis. Table 14.1 outlines the DSM IV criteria necessary for diagnosis and some of the commonly listed clinical features. 1 [Level 4] Table 14.1 Diagnosing delirium Clinical Diagnosis All of the following should be present: - Disordered conscious level - Change in cognition - Fluctuation - Developing over a short period - Aetiologically related to a medical condition Associated Clinical Features Some of the following may be present: - Poor concentration - Disorientation - Loss of short term memory - Hallucinations - Paranoid ideas - Restlessness or aggression Delirium may be hyperactive or hypoactive. Hypoactive delirium is more common than hyperactive delirium in palliative care patients, although is often not diagnosed. 5 [Level 4] Features of hypoactive delirium include slowed motor function, lethargy, confusion and decreased awareness and interaction with their surroundings. These features may mimic depression. 5 [Level 2-] The role of neuroleptic medication in hypoactive delirium is uncertain at present. 5 [Level 4]
2 Reversible causes of delirium Delirium is often reversible although this may not apply in the last hours of life. 4 [Level 2-] Some of the potentially reversible causes of delirium are listed in Table , 6 [Level 4] Table 14.2 Reversible causes of delirium Alcohol Biochemical abnormalities e.g. hypercalcaemia, uraemia Cardiovascular causes Cerebral pathology Constipation Drugs Haematological causes Infections Nutritional deficiencies Withdrawal from alcohol / nicotine Withdrawal from drugs e.g. antipsychotics, opioids, benzodiazepines Management of delirium It is important to use both pharmacological and non-pharmacological measures in the management of a patient with delirium. 2 [Level 4] Non-pharmacological measures may include: a well-lit and quiet room, familiar faces, explanation, reassurance and the avoidance of isolation and loneliness. 2 [Level 4] Drugs, in particular opioids, are a common cause of delirium. A review of medication, including drugs recently discontinued, should be performed. 4 [Level 2-] If the patient is distressed, delirium may require specific drug management. Table 14.3 lists the pharmacological options. 7, 8, 9, 10 [Level 2+] Neuroleptics such as haloperidol and atypical antipsychotics remain the drugs of choice. 6 [Level 2++] Benzodiazepines may exacerbate delirium and should be used with caution. 6, 7, 8 [Level 2++] The aim of treatment should be to control the delirium. The treatment may at times cause a reduction in the level of consciousness. 9 [Level 4] The aim of treatment and any expected change in level of consciousness should be discussed with the patient, relatives and multi-disciplinary team where possible and documented in the case notes. 11 [Level 4] Figure 14.1 outlines a pharmacological approach to the management of delirium. Drugs should only be used when the delirium is causing distress to the patient and should be titrated according to clinical need. The manifestation of distress may influence the treatment used e.g. overlying anxiety may be better treated with benzodiazepines; paranoia may be better managed with neuroleptics. 7, 8, 12 [Level 4]
3 Committee on Safety of Medicines (CSM) warning for olanzapine and risperidone 13, 15 [Level 2] Olanzapine and risperidone are associated with an increased risk of stroke in elderly patients with dementia. The CSM has advised the following: Risperidone or Olanzapine should not be used for treating behavioural symptoms of dementia. In acute psychotic conditions in elderly patients with dementia, risperidone should be limited to short term use under specialist advice. Olanzapine is not licensed for the management of acute psychoses. The possibility of cerebrovascular events should be considered carefully before treating any patients with a history of stroke or transient ischaemic attacks. Risk factors for cerebrovascular disease should also be considered e.g. hypertension, diabetes, smoking, atrial fibrillation. Observational studies suggest that similar to the atypical antipsychotics, treatment with conventional antipsychotic drugs may increase mortality. 16 [Level 3] Mental Capacity Where the patient is shown to lack the capacity to consent to treatment, the Mental Capacity Act 2005 must be followed. Lasting Power of Attorney, Advanced Decisions and Independent Mental Capacity Advocates should be utilised where appropriate. 11, 14 [Level 4]
4 Figure 14.1 Pharmacological management of delirium in advanced cancer 7, 8, 10 [Level 4] Diagnosis of delirium using DSMIV criteria. Reversible causes investigated and treated where appropriate. NB. Drug treatment only indicated where the patient is distressed. Is patient able to swallow? Start haloperidol 0.5mg- 5mg orally at night. YES NO Prescribe haloperidol 0.5mg-3mg subcutaneously prn. Consider haloperidol 3mg-10mg as a subcutaneous infusion via a Are there any side effects? NO Continue regimen. YES Consider atypical anti-psychotic e.g. Olanzapine. Dose: 2.5mg orally at night and as required. NB. Subcutaneous: oral potency of haloperidol is 2:1.
5 6, 7, Table 14.3 Pharmacological options for the management of delirium in advanced disease 8, 9 [Level 2+] Name of drug Class of drug Dosage Side effects Notes Haloperidol Long acting dopamine antagonist. Oral 0.5mg-5mg tds orally. Maximum dose 30mg/24 hours Subcutaneous 1.5mg-5mg as subcutaneous bolus dose every 8 hours 5mg-10mg subcutaneously via Maximum parenteral dose is 18mg in 24 hours. Extra-pyramidal reactions. First line treatment for delirium. Note. The parenteral dose should be lower than the corresponding oral dose because of the absence of first pass metabolism. The same dose should not be prescribed for both routes. Levomepromazine Long acting phenothiazine. Oral 12.5mg-50mg orally daily. Subcutaneous 6.25mg-25mg as subcutaneous bolus dose every 6-8 hours 12.5mg-200mg subcutaneously via High risk of sedation High doses may precipitate seizures. In a patient with a history of seizures consider the addition of midazolam. Note. The parenteral dose should be lower than the corresponding oral dose because of the absence of first pass metabolism. The same dose should not be prescribed for both routes. Olanzapine Atypical antipsychotic. Usually given orally 2.5mg-10mg daily Can be given by CSCI but specialist advice should be sought Weight gain, drowsiness, dry mouth. See guidelines for CSM warning. Risperidone Atypical antipsychotic. 500micrograms orally initially. Increase by 500micrograms bd alternate days. Maintenance dose usually 1-3mg / day. Maximum dose is 4mg daily. Weight gain, drowsiness, dry mouth. See guidelines for CSM warning. May need lower starting dose and slower titration in elderly patients and patients with renal impairment. Interacts with CYP2D6 inhibitors e.g. fluoxetine so some drug interactions may be significant. Midazolam Short acting benzo-diazepine. 2.5mg-10mg as subcutaneous bolus doses. 10mg-100mg subcutaneously via Possible paradoxical agitation. Will not improve cognition in delirium. Diazepam Short acting benzodiazepine. 2mg-15mg orally daily in divided doses. 10mg via rectal route prn. 5mg-10mg intravenously prn. Possible paradoxical agitation. Will not improve cognition in delirium. Phenobarbital Long acting barbiturate. 100mg-200mg as bolus intramuscular injections. 600mg-2400mg subcutaneously via Used in the dying phase to as third line agent to control agitation/delirium. Can use sodium chloride 0.9% or water as diluent but anecdotal evidence suggests may get fewer site reactions with sodium chloride 0.9%.
6 14.3 STANDARDS 1. The DSM IV criteria should be used in the diagnosis of delirium. 1 [Grade D] 2. Reversible causes of delirium should be treated where appropriate. 3, 4 [Grade D] 3. All patients should have a clinical examination at initial assessment of delirium. 3, 4 [Grade D] 4. All patients should have a review of medication at initial assessment of delirium. 3, 4 [Grade D] 5. The reason for the use of psychotropic medication should be documented in the case notes. 11 [Grade D] 6. Haloperidol is the drug of choice for the management of delirium where the cause is unknown. 6, 7 [Grade C] 7. Inpatients with delirium should be reviewed every four hours to ensure adequate symptom control. 11 [Grade D] 14.4 REFERENCES 1. American Psychiatric Association. Practice guidelines for the treatment of patients with delirium. Am J Psychiat 1999; 156(5 Suppl): Centeno C, Sanz A, Bruera E. Delirium in advanced cancer patients. Palliat Med 2004; 18: Casarett DJ, Inouye SK. Diagnosis and management of delirium near the end of life. Ann Intern Med. 2001; 135: Lawlor PG, Gagnon B, Mancini IL, Pereira JL, Hanson J, Suarez-Almazor ME et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer. Arch Intern Med 2000; 160(6): Spiller JA. Hypoactive delirium: assessing the extent of the problem for inpatient specialist palliative care. Palliat Med 2006; 20: Inouye SK, Bogardus ST, Charpentier PA, Leo-Summers L, Acampora D, Holford TR et al. A multicomponent intervention to prevent delirium in hospitalised older patients. New Engl J Med 1999; 340(9): Breitbart W, Marotta R, Platt M, Weisman H, Derevenco M, Grau C et al. A double blind trial of haloperidol, chlorpromazine and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996; 153(2): Bottomley DM, Hanks G. Subcutaneous midazolam infusion in palliative care. J Pain Symptom Manage 1990; 5: De Graeff A, Dean M. Palliative sedation therapy in the last weeks of life: a literature review and recommendations for standards. J Palliat Med 2007; 10: Jackson KC, Lipman AG. Drug therapy for delirium in terminally ill patients. Cochrane Database of Systematic Reviews 2004, Issue 2. Art. No.: CD DOI: / CD Merseyside and Cheshire Palliative Care Network Audit Group. Management of delirium in advanced cancer. Expert Consensus. July Twycross R. Psychological symptoms. In: Twycross R (ed). Symptom Control in Advanced Cancer 2nd edition. Oxford: Radcliffe Medical Press; 1997:
7 13. Committee on Safety of Medicines (CSM) New advice issued on risperidone and olanzapine. March Available from: [Last accessed 23 April 2009] 14. Department for Constitutional Affairs. Mental Capacity Act 2005 Code of Practice. London Available from: [Last accessed 11 April 2009] 15. Kleijer BC, Van Marum RJ, Egberts AC, Jansen PA, Knol W, Heerdink ER. Risk of cerebrovascular events in elderly users of antipsychotics. J Psychopharmacol 2009; 23(8): Electronic Medicines Compendium. Summary of Product Characteristics for Haldol 2mg/ml liquid. Available from: [Last accessed 14 th November 2009] 14.5 CONTRIBUTORS Lead Contributors Dr C Finnegan Specialist Registrar in Palliative Medicine St Johns Hospice Wirral External Reviewer Dr A Thorns Consultant in Palliative Medicine St Pilgrims Hospice in Thanet Margate Dr F Ahmad Specialty Registrar in Palliative Medicine Loros Hospice Leicester Dr K Marley Specialty Registrar in Palliative Medicine Marie Curie Hospice Liverpool Dr C Lewis-Jones Consultant in Palliative Medicine/Medical Director St Johns Hospice Wirral and Wirral University Teaching Hospital NHS Foundation Trust Dr A Fountain Consultant in Palliative Medicine Halton and St Helens Primary Care Trust Halton Dr L Beddows Consultant in Old Age Psychiatry St Catherine s Hospital Wirral
1. GUIDELINES FOR THE MANAGEMENT OF AGITATION IN ADVANCED CANCER
1. GUIDELINES FOR THE MANAGEMENT OF AGITATION IN ADVANCED CANCER 1.1 GENERAL PRINCIPLES There are many causes of agitation in palliative care patients, which makes recommendations for treatment difficult.
More informationDelirium. Assessment and Management
Delirium Assessment and Management Goals and Objectives Participants will: 1. be able to recognize and diagnose the syndrome of delirium. 2. understand the causes of delirium. 3. become knowledgeable about
More informationDelirium. A Plan to Reduce Use of Restraints. David Wensel DO, FAAHPM Medical Director Midland Care
Delirium A Plan to Reduce Use of Restraints David Wensel DO, FAAHPM Medical Director Midland Care Objectives Define delirium Describe pathophysiology of delirium Understand most common etiologies Define
More informationLearning Objectives. Delirium. Delirium. Delirium. Terminal Restlessness 3/28/2016
Terminal Restlessness Dr. Christopher Churchill St. Cloud VA Health Care System EC&R Service Line Director & Medical Director Hospice & Palliative Care March 31, 2016 Learning Objectives Different Terminology
More informationCritical Care Pharmacological Management of Delirium
Critical Care Pharmacological Management of Delirium Policy Title: in the Critical Care Unit Executive Summary: This policy provides guidance Pharmacological Management of delirium in the Critical Care
More informationPAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE
PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE Reference: DCM029 Version: 1.1 This version issued: 07/06/18 Result of last review: Minor changes Date approved by owner (if applicable): N/A
More informationDelirium. Dr. Lesley Wiesenfeld. Deputy Psychiatrist in Chief, Mount Sinai Hospital. Dr. Carole Cohen
Delirium Dr. Lesley Wiesenfeld Deputy Psychiatrist in Chief, Mount Sinai Hospital Dr. Carole Cohen Department of Psychiatry, University of Toronto and Sunnybrook Health Sciences Centre Case Study Mrs B
More informationSupporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety
Agitation & Anxiety (Exclude or treat REVERSIBLE causes*) Patient is anxious / frightened, but lucid Patient is confused, agitated and / or hallucinating MIDAZOLAM 2.5-5mg s/c (Max total 24 hour dose of
More informationPAIN MANAGEMENT Person established taking oral morphine or opioid naive.
PAIN MANAGEMENT Person established taking oral morphine or opioid naive. Important; it is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member
More informationDelirium. Approach. Symptom Update Masterclass:
Symptom Update Masterclass: Delirium Jason Boland Senior Clinical Lecturer and Honorary Consultant in Palliative Medicine Wolfson Centre for Palliative Care Research Hull York Medical School University
More informationCritical Care Pharmacological Management of Delirium
Critical Care Pharmacological Management of Delirium Policy Title: in the Critical Care Unit Executive Summary: This policy provides guidance Pharmacological Management of delirium in the Critical Care
More informationGUIDELINES FOR CONVERSION FROM A STRONG OPIOID TO METHADONE
GUIDELINES FOR CONVERSION FROM A STRONG OPIOID TO METHADONE GENERAL PRINCIPLES Methadone may be used as a strong opioid alternative when severe cancer-related pain responds poorly to other opioids, or
More informationSiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]
SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA [compatible with NICE guidance] Medicines Management Committee August 2002 For review August 2003 Rationale The SiGMA algorithm
More informationPRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT
PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT A collaboration between: St. Rocco s Hospice, Bridgewater Community Healthcare NHS Trust, NHS Warrington Clinical Commissioning Group,
More informationCare in the Last Days of Life
Care in the Last Days of Life Introduction This guideline is an aid to clinical decision making and good practice in person-centred care for patients who are deteriorating and at risk of dying. The patient
More informationCambridge University Press Effective Treatments in Psychiatry Peter Tyrer and Kenneth R. Silk Excerpt More information
Organic disorders 1 Delirium Based on Delirium by Laura Gage and David K. Conn in Effective Treatments in Psychiatry, Cambridge University Press, 2008 Introduction Delirium needs treatment for both its
More informationFor patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.
Bedfordshire Palliative Care Palliative Care Medicines Guidance This folder has been produced to support professionals providing palliative care in any setting. Its aim is to make best practice in palliative
More informationSymptom Management Pocket Guides: DELIRIUM
Symptom Management Pocket Guides: DELIRIUM August 2010 DELIRIUM Page Considerations. 1 Assessment 2 Diagnosis. 3 Non-Pharmacological treatment 3 Pharmacological treatment. 5 Mild Delirium... 6 Moderate
More informationDelirium. Quick reference guide. Issue date: July Diagnosis, prevention and management
Issue date: July 2010 Delirium Diagnosis, prevention and management Developed by the National Clinical Guideline Centre for Acute and Chronic Conditions About this booklet This is a quick reference guide
More informationGUIDELINES FOR THE USE OF PSYCHOSTIMULANTS IN PALLIATIVE CARE
GUIDELINES FOR THE USE OF PSYCHOSTIMULANTS IN PALLIATIVE CARE 36.1 GENERAL PRINCIPLES Current research evidence supports the use of psychostimulants in palliative care in four areas: depression; 1, 2 opioid
More informationThe Agitated. Older Patient: old. What To Do? Michelle Gibson, MD, CCFP Presented at Brockville General Hospital Rounds, May 2003
Focus on CME at Queen s University Focus on CME at Queen s University The Agitated The Older Patient: What To Do? Michelle Gibson, MD, CCFP Presented at Brockville General Hospital Rounds, May 2003 Both
More informationAntipsychotic Medications
TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood
More informationControlled Document Number: Version Number: 1. Controlled Document Sponsor: Controlled Document Lead (Author): On: July Review Date: July 2020
Guidelines for the Use of Naloxone in Palliative Care in Adult Patients CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: Controlled Document Number: Version Number: 1 Controlled Document Sponsor: Controlled
More informationDelirium in Cancer: Psychopharmacologic Management
Delirium in Cancer: Psychopharmacologic Management William Breitbart, MD Professor and Chief, Psychiatry Service Memorial Sloan-Kettering Cancer Center New York, New York Delirium in Patients with Cancer
More informationFormulary and Clinical Guideline Document Pharmacy Department Medicines Management Services
Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services VIOLENCE, AGGRESSION OR SEVERE BEHAVIOURAL DISTURBANCE Introduction During an acute episode or illness, some
More informationEmergency Control of the Acutely Disturbed Adult Patient GUIDELINES ON EMERGENCY CONTROL OF THE ACUTELY DISTURBED ADULT PATIENT... 2 ACTION...
Delirium Toolkit Emergency Control of the Acutely Disturbed Adult Patient Table of Contents GUIDELINES ON EMERGENCY CONTROL OF THE ACUTELY DISTURBED ADULT PATIENT... 2 ACTION... 2 AFTERCARE... 3 NOTES...
More informationManagement of Delirium in Hospice Patients
Presentation Objectives Management of Delirium in Hospice Patients Lynn Williams, BSPharm Clinical Pharmacist Hospice Pharmacy Solutions Identify the clinical features of delirium Understand the underlying
More informationManagement of Severe Agitation
Management of Severe Agitation Key Points 1. The management of the severely agitated or violent patient embraces psychological, physical and pharmacological approaches. 2. Psychological methods focus on
More informationInterprofessional Webinar Series
Interprofessional Webinar Series Assessment and Management of Delirium Pauline Lesage, MD, LLM Physician Educator MJHS Institute for Innovation in Palliative Care Disclosure Slide Pauline Lesage, MD, LLM,
More information4. GUIDELINES FOR THE USE OF ANTI- EPILEPTICS IN PALLIATIVE CARE
4. GUIDELINES FOR THE USE OF ANTI- EPILEPTICS IN PALLIATIVE CARE 4.1 GENERAL PRINCIPLES Anti-epileptic drugs should be considered in all patients with primary or secondary brain tumours who have a history
More informationDEMENTIA AND MEDICATION
DEMENTIA AND MEDICATION Dr. Siobhan Ni Bhriain, MRCP, MRCPsych. Clinical Director, Tallaght and SJH MHS, Consultant Old Age Psychiatrist, Chair, DSIDC Steering Committee. SUMMARY OF TODAY S TALK Dementia-definition,
More informationIn our patients the cause of seizures can be broadly divided into structural and systemic causes.
Guidelines for the management of Seizures Amalgamation and update of previous policies 7 (Seizure guidelines, ND, 2015) and 9 (Status epilepticus, KJ, 2011) Seizures can occur in up to 15% of the Palliative
More informationSymptom Management Guidelines for End of Life Care
Symptom Management Guidelines for End of Life Care The following pages are guidelines for the management of common symptoms in the last few days of life. General principles: 1. Consider how symptoms can
More informationRenal Palliative Care Last Days of Life
Renal Palliative Care Last Days of Life Introduction This guideline is an aid to clinical decision-making and good practice for patients with stage 4-5 chronic kidney disease (egfr
More informationGUIDELINES FOR THE MANAGEMENT OF PALLIATIVE CARE PATIENTS WITH A HISTORY OF SUBSTANCE MISUSE
GUIDELINES FOR THE MANAGEMENT OF PALLIATIVE CARE PATIENTS WITH A HISTORY OF SUBSTANCE MISUSE 41.1 GENERAL PRINCIPLES The ICD 10 diagnostic criteria for dependency syndrome are listed in Table 41.1 below.
More informationGuidelines for the Assessment and Management of Delirium in the Last Hours and Days of Life
D Monnery, 1 K Gaunt, 2 P Shepherd, 2 G Holland, 3 K Nolan, 4 R Telfer, 4 F Ahmad, 5 C Finnegan 6 (Guideline Development Lead) 1 University Hospital Aintree NHS Foundation Trust; 2 Woodlands Hospice, Aintree;
More informationThe last days of life in hospital and at home
The last days of life in hospital and at home Beaumont Multi-disciplinary Palliative Care Study Day 28/9/2017 Dr Sarah McLean Consultant in Palliative Medicine St Francis Hospice Beaumont Hospital Overview
More informationCare of the Dying Management in Severe Renal Failure
Care of the Dying Management in Severe Renal Failure Clinical Guideline Early diagnosis of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance
More informationMMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life
MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life The following pages are guidelines for the management of common symptoms for a person thought to be
More informationDrug induced delirium
Drug induced delirium Knut Erik Hovda, MD, PhD, FACMT, FEAPCCT The Norwegian CBRNe Centre of Medicine Department of Acute Medicine Oslo University hospital Content 1. Introduction 2. Risk factors 3. Prevalence
More informationSupportive Care. End of Life Phase
Supportive Care End of Life Phase Guidelines for Health Care Professionals In the care of patients with established renal failure who are in the last days of life References: Chambers E J (2004) End of
More informationg Prevention, Diagnosis, and Management in Palliative Care
8/3/2012 Improving p g Prevention, Diagnosis, g and Management in Palliative Care MN Rural Palliative Care Networking Group Quarterly Education Session June 27,2012 Sandra W. Gordon-Kolb, MD, MMM, CPE
More informationPRESCRIBING PRACTICE IN DELIRIUM. John Warburton Critical Care Pharmacist
PRESCRIBING PRACTICE IN DELIRIUM John Warburton Critical Care Pharmacist Learning outcomes Modifiable medication risk factors for delirium An appreciation of contributing factors modifiable with medicines
More informationSPAGG. Coversheet for Specialist Palliative Audit and Guideline Group Agreed Documentation
SPAGG Coversheet for Specialist Palliative Audit and Guideline Group Agreed Documentation This sheet is to accompany all documentation agreed by SPAGG. This will assist maintenance of the guidelines as
More informationDelirium in the Elderly
Delirium in the Elderly ELITE 2017 Liza Genao, MD Division of Geriatrics Why should we care about delirium? It is: common associated with high mortality associated with increased morbidity Very much under-recognized
More information( delirium ) 15%- ( extrapyramidal syndrome ) risperidone olanzapine ( extrapyramidal side effect ) olanzapine ( Delirium Rating Scale, DRS )
2005 6 48-52 Olanzapine 30% ( delirium 5%- Haloperidol ( extrapyramidal syndrome risperidone ( extrapyramidal side effect ( Delirium Rating Scale, DRS ( Delirium ( Olanzapine ( Delirium Rating Scale, DRS
More informationAlgorithms for Symptom Management. In End of Life Care
Algorithms for Symptom Management In End of Life Care The Use of Drugs Beyond Licence (off label) -The Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK regulates the activity of the
More informationSpecialist Palliative Care Audit and Guidelines Group (SPAGG)
Specialist Palliative Care Audit and Guidelines Group (SPAGG) Clinical Guideline for the Prescribing and Administration of Furosemide via continuous subcutaneous infusion (CSCI) for Heart Failure Patients
More informationPAIN MANAGEMENT Patient established on oral morphine or opioid naive.
PAIN MANAGEMENT Patient established on oral morphine or opioid naive. Important; It is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member
More informationDELIRIUM IN ICU: Prevention and Management. Milind Baldi
DELIRIUM IN ICU: Prevention and Management Milind Baldi Contents Introduction Risk factors Assessment Prevention Management Introduction Delirium is a syndrome characterized by acute cerebral dysfunction
More informationCare of the Dying. For dosing in severe renal impairment see separate guidance for care of the dying in severe renal failure.
Care of the Dying Early diagnosis of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance covers the prescribing and management of patients
More informationCare of the Dying Management in Severe Renal Failure
Care of the Dying Management in Severe Renal Failure Clinical Guideline Early recognition of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance
More informationDEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
More informationRenal Prescribing at End of Life Guidance for Anticipatory prescribing for patients in renal failure (egfr<30) at the end of life
Guidance for Anticipatory prescribing for patients in renal failure (egfr
More informationAGITATION THE SCOPE AND IMPACT OF DELIRIUM AGITATION, RESTLESSNESS, CONFUSION AND DELIRIUM
ADVANCE CARE PLANNING AND END OF LIFE CARE UNIT NO. 6 AGITATION Dr Tan Yew Seng ABSTRACT Agitation and delirium are commonly encountered symptoms in palliative care. Based on the clinical features, delirium
More informationPSYCHOTROPIC SOLUTIONS
PSYCHOTROPIC SOLUTIONS A proactive approach to antipsychotic medication management A Quality Use of Medicines initiative by Choice Aged Care Copyright 2018 Key Senate Committee Recommendations: All RACF
More informationDELIRIUM. Approach and Management
DELIRIUM Approach and Management By Dr. K.S. Jacob, Professor of Psychiatry and Dr. Anju Kuruvilla, Professor of Psychiatry, Christian Medical College, Vellore. Based on a chapter in the book Psychiatric
More informationQUESTIONS What are the effects of interventions at the end of life in people with delirium caused by underlying terminal illness?...
at the end of life Search date February 29 Paul Keeley ABSTRACT INTRODUCTION: is common in the last weeks of life, occurring in 26% to 44% of people with advanced cancer in hospital, and in up to 88% of
More informationSECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS
SECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS Formulary and Prescribing Guidelines 9.1 Introduction Movement disorders and extrapyramidal side effects can manifest in the
More informationDelirium in the Elderly
Delirium in the Elderly ELITE 2015 Mamata Yanamadala M.B.B.S, MS Division of Geriatrics Why should we care about delirium? It is: common associated with high mortality associated with increased morbidity
More informationGUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS
GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS Bristol Palliative Care Collaborative Contact Numbers: Hospital Specialist Palliative Care Teams: North Bristol 0117 4146392 UH Bristol 0117
More informationBRAIN. Tumor byproducts. Autonomic nerves. Somatic nerves. Host immune cells. Cytokines
Patient s Problems Pain (80%) Fatigue (90%) Weight Loss (80%) Lack of Appetite (80%) Nausea, Vomiting (90%) Anxiety (25%) Shortness of Breath (50%) Confusion-Agitation (80%) Tumor Mass Tumor Function Somatic
More informationGuidelines for the management of agitation in the last weeks of life
Guidelines for the management of agitation in the last weeks of life 14.09.17 Overview 1. Aim 2. Literature Review 3. Current Standards 4. Audit Results 5. Patient Representative Input 6. Proposed New
More informationEvidence-Based Treatment of Delirium in Patients With Cancer William Breitbart and Yesne Alici
Published Ahead of Print on March 12, 2012 as 10.1200/JCO.2011.39.8784 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2011.39.8784 JOURNAL OF CLINICAL ONCOLOGY R E V I E W A R T I
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More informationDrugs that poison the elderly
Drugs that poison the elderly Brent Tipping Sub-specialist Geriatrician and Specialist Physician Division of Geriatric Medicine, Department of Medicine University of the Witwatersrand To treat or not to
More informationFor more information about how to cite these materials visit
Author(s): Rachel Glick, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Noncommercial Share Alike 3.0 License: http://creativecommons.org/licenses/by-nc-sa/3.0/
More informationSymptom Management Challenges at End-of-Life
Symptom Management Challenges at End-of-Life Amanda Lovell, PharmD, BCGP Clinical Pharmacist- Inpatient Units Optum Hospice Pharmacy Services February 15, 2018 Hospice Pharmacy Services Objectives Identify
More informationEPEC-G Handout: Delirium. Delirium is a very common and distressing symptom of older persons during the last
EPEC-G Handout: Delirium 1. Abstract Delirium is a very common and distressing symptom of older persons during the last stages of life. Most research on delirium has dealt with hospitalized older persons
More informationAppendix D: Included Studies adverse effects review
DELIRIUM APPENDICES (Draft for Consultation) Appendix D: Included Studies adverse effects review Table D1: Studies directly comparing two antipsychotic agents in delirium Author Study design Setting Age
More informationPRESCRIBING GUIDELINES
The Maudsley The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust PRESCRIBING GUIDELINES 10th Edition David Taylor Carol Paton Shitij Kapur informa healthcare Contents Authors
More informationGUIDELINES FOR PRESCRIBING AT THE END OF LIFE FOR PATIENTS WITH RENAL IMPAIRMENT (estimated glomerular filtration rate<30)
GUIDELINES FOR PRESCRIBING AT THE END OF LIFE FOR PATIENTS WITH RENAL IMPAIRMENT These guidelines have been produced in collaboration with Dr Lucy Smyth, Consultant in Renal Medicine, Royal Devon and Exeter
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationGUIDELINES FOR DIAGNOSIS, PREVENTION AND TREATMENT OF DELIRIUM IN THE INPATIENT SETTING
GUIDELINES FOR DIAGNOSIS, PREVENTION AND TREATMENT OF DELIRIUM IN THE INPATIENT SETTING Policy Details NHFT document reference MMG033 Version Final Date Ratified May 2016 Ratified by Medicines Management
More informationAntiepileptics Audit
Antiepileptics Audit Dr Kate Marley Dr Lucy Potter Dr Melanie Brooks Dr Averil Fountain CNS Sue Croft External Reviewer: Dr A Nicolson Consultant Neurologist c CURRENT GUIDANCE 4.1 GENERAL PRINCIPLES Anti-epileptic
More informationDelirium Screening Tools: Just- In- Time Education and Evaluation Using the EMR
Delirium Screening Tools: Just- In- Time Education and Evaluation Using the EMR Implementation of an EMR based protocol for detection of delirium in elderly Medical and palliative care patients Parul Goyal,
More informationDebra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017
Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist HMS Training Webinar January 27, 2017 1 Describe nationwide prevalence and types of elderly dementia + define BPSD Define psychotropic
More informationBehavior Management in Children with Cancer
Behavior Management in Children with Cancer Anna (Nina) Muriel, MD, MPH Chief, Division of Pediatric Psychosocial Oncology Department of Psychosocial Oncology and Palliative Care Behavior matters Behavior
More informationWaterloo Wellington (WW) Symptom Management Guideline for the End of Life (EOL) Medication Order Set for Long Term Care (LTC)
Waterloo Wellington (WW) Symptom Management Guideline for the End of Life (EOL) Medication Order Set for Long Term Care (LTC) May 2018 THE WATERLOO WELLINGTON SYMPTOM MANAGEMENT GUIDELINE FOR THE END OF
More informationSyringe driver in Palliative Care
Syringe driver in Palliative Care Introduction: Syringe drivers are portable, battery operated devices widely used in palliative care to deliver medication as a continuous subcutaneous infusion over 24
More informationHome Care and Hospice Association of New Jersey Annual Conference 2017
Home Care and Hospice Association of New Jersey Annual Conference 2017 I D E N T I F I C A T I O N A N D M A N A G E M E N T O F D E L I R I U M E L I Z A B E T H M A G E R - O C O N N O R A C H P N DR
More informationSYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL
SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL If a patient is believed to be approaching the end of their life, medication should be prescribed in anticipation
More informationThe place for treatments of associated neuropsychiatric and other symptoms
The place for treatments of associated neuropsychiatric and other symptoms Luca Pani dg@aifa.gov.it London, 25 th November 2014 Workshop on Alzheimer s Disease European Medicines Agency London, UK Public
More informationHHS Public Access Author manuscript Curr Opin Support Palliat Care. Author manuscript; available in PMC 2017 December 01.
Neuroleptics in the Management of Delirium in Patients with Advanced Cancer David Hui, MD, MSc, Rony Dev, MD and Eduardo Bruera, MD Department of Palliative Care and Rehabilitation Medicine, MD Anderson
More informationTaking care of the terminally ill cancer patient: delirium as a symptom of terminal disease
Annals of Oncology 15 (Supplement 4): iv199 iv203, 2004 doi:10.1093/annonc/mdh927 Taking care of the terminally ill cancer patient: delirium as a symptom of terminal disease L. Michaud 1,2, B. Burnand
More informationGuidelines: EOLC Symptom Control for Patients with Normal Renal Function (in Wandsworth)
Guidelines: EOLC Symptom Control for Patients with Normal Renal Function (in Wandsworth) Policy Number : DC020 Issue Date: October 2014 Review date: October 2016 Policy Owner: Head Community Services Monitor:
More informationCognitive disorders. Dr S. Mashaphu Department of Psychiatry
Cognitive disorders Dr S. Mashaphu Department of Psychiatry Delirium Syndrome characterised by: Disturbance of consciousness Impaired attention Change in cognition Develops over hours-days Fluctuates during
More informationEuropean PSUR Work Sharing Project CORE SAFETY PROFILE. Lendormin, 0.25mg, tablets Brotizolam
European PSUR Work Sharing Project CORE SAFETY PROFILE Lendormin, 0.25mg, tablets Brotizolam 4.2 Posology and method of administration Unless otherwise prescribed by the physician, the following dosages
More informationRisk factors for incident delirium in acute medical in-patients. A systematic review
Risk factors for incident delirium in acute medical in-patients. A systematic review Reviewers Emily Cull RN, BN(Hons) 1 Bridie Kent PhD, BSc(Hons), RN 2 Dr Nicole M. Phillips DipAppSc(Nsg), BN, GDipAdvNsg(Educ),
More informationOlanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015)
1. Key Points Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015) 1.1 Olanzapine long acting injection (LAI) is indicated for the maintenance
More informationDelirium in the ICU: Prevention and Treatment. Delirium Defined Officially. Delirium: Really Defined. S. Andrew Josephson, MD
Delirium in the ICU: Prevention and Treatment S. Andrew Josephson, MD Director, Neurohospitalist Service Medical Director, Inpatient Neurology June 2, 2011 Delirium Defined Officially (DSM-IV-TR) criteria
More informationDelirium. Delirium is characterized by an acute onset (hours or days) and fluctuating course of deterioration in mental functioning.
Delirium Delirium is characterized by an acute onset (hours or days) and fluctuating course of deterioration in mental functioning. DELIRIUM IS A MEDICAL EMERGENCY! Delirium: Hallmark Features Inattention-
More informationSUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS
SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS Guideline Title Summary of Product Characteristics for Benzodiazepines as Anxiolytics or Hypnotics Legislative basis Directive
More informationEffects of High Dose Opioids and Sedatives on Survival in Terminally Ill Cancer Patients
282 Journal of Pain and Symptom Management Vol. 21 No. 4 April 2001 Original Article Effects of High Dose Opioids and Sedatives on Survival in Terminally Ill Cancer Patients Tatsuya Morita, MD, Junichi
More informationHydration at the End of Life:
Hydration at the End of Life: A systematic literature review and audit of current practice November 12 th 2015 Dr Alison Coackley- Consultant in Palliative Medicine, Clatterbridge Cancer Centre Dr Catherine
More informationConservative Management of Uraemia
Conservative Management of Uraemia Information for Health Professionals Renal Department The York Hospital and Scarborough Hospital Tel: 01904 725370 For more information, please contact: The Renal Specialist
More informationHaloperidol and risperidone in the treatment of delirium and its subtypes
Eur. J. Psychiat. Vol. 25, N. 2, (59-67) 2011 Keywords: Delirium; Treatment; Haloperidol; Risperidone; Antipsychotics. Haloperidol and risperidone in the treatment of delirium and its subtypes Soenke Boettger*
More informationPSYCHOTROPIC SOLUTIONS
PSYCHOTROPIC SOLUTIONS A proactive approach to antipsychotic medication management A Quality Use of Medicines initiative by Choice Aged Care Copyright 2018 Hello everyone. Today we will be discussing the
More informationChapter 17. Psychoses. Classifications of Psychoses. Schizophrenia. Factors Attributed to Development of Psychoses
Chapter 17 Psychoses Drugs for Psychoses Delusions Hallucinations Illusions Paranoia Upper Saddle River, New Jersey 07458 All rights reserved. Classifications of Psychoses Acute episode Chronic episode
More informationGUIDELINES FOR THE ASSESSMENT AND MANAGEMENT OF MAJOR HAEMORRHAGE IN PALLIATIVE CARE
GUIDELINES FOR THE ASSESSMENT AND MANAGEMENT OF MAJOR HAEMORRHAGE IN PALLIATIVE CARE 25.1 GENERAL PRINCIPLES There is no agreed definition regarding major haemorrhage within the palliative care setting.
More information